Valuation: Valneva SE Pref.

Market Cap 433M 494M 400M 370M 702M 46.98B 714M 4.79B 1.86B 23.15B 1.86B 1.82B 80.18B P/E 2026 *
-6.29x
P/E 2027 * 6.08x
Enterprise Value 561M 640M 518M 479M 909M 60.86B 924M 6.21B 2.41B 29.99B 2.4B 2.35B 104B EV / Sales 2026 *
3.7x
EV / Sales 2027 * 1.68x
Free-Float
97.36%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Valneva SE Pref.

Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 500M
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.25%+1.70%+419.39%+621.71% 40.39B
+1.10%+7.77%+28.18%-3.96% 34.38B
-0.16%+8.12%+27.85%+62.55% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.35%+0.09% - - 16.64B
-3.33%+3.15%+71.30%+131.94% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.79%+8.88%+106.63%+106.63% 13.75B
Average +0.16%+4.45%+84.47%+122.96% 27.33B
Weighted average by Cap. +0.05%+5.02%+95.76%+141.20%

Financials

2026 *2027 *
Net sales 152M 173M 140M 130M 246M 16.46B 250M 1.68B 653M 8.11B 650M 636M 28.09B 294M 335M 271M 251M 476M 31.88B 484M 3.25B 1.26B 15.71B 1.26B 1.23B 54.4B
Net income -66.01M -75.29M -60.87M -56.39M -107M -7.16B -109M -730M -284M -3.53B -283M -276M -12.21B 70.5M 80.41M 65.01M 60.22M 114M 7.64B 116M 779M 303M 3.77B 302M 295M 13.04B
Net Debt 128M 146M 118M 109M 207M 13.88B 211M 1.42B 550M 6.84B 548M 536M 23.68B 60.02M 68.45M 55.34M 51.26M 97.19M 6.51B 98.82M 664M 258M 3.21B 257M 251M 11.1B
Logo Valneva SE Pref.
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.285EUR
Average target price
5.233EUR
Spread / Average Target
+129.03%

Quarterly revenue - Rate of surprise